Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab in adenosquamous pancreatic or ampullary cancer
NCT04116073Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2020
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in Adenosquamous Carcinoma Of The Pancreas (ASCP) and Ampullary cancer (AC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Disease Control Rate at 4 months. Started Apr 2020; status: completed.
02
Drugs
retifanlimab
03
Conditions
Adenosquamous Carcinoma Of The Pancreas (ASCP)Ampullary cancer (AC)
Beyond the preview
Go deeper on NCT04116073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116073.